Crescent Biopharma Q3 net loss widens 53% to $37.73 million
CBIO•Crescent Biopharma’s third-quarter 2026 net loss widened 53% year over year to $37.73 million. The company had $289.4 million in cash and cash equivalents at September 30, which it expects to fund operations into the second half of 2028.
1. Quarterly results
Crescent Biopharma’s third-quarter 2026 net loss widened 53% year over year to $37.73 million. Research and development expenses rose 69% to $34.31 million, supporting increased ASCEND clinical development and preparations for APOLLO’s initiation.
2. Cash and trials
Cash and cash equivalents totaled $289.4 million at September 30, which the company expects to fund operations into the second half of 2028. Initial CR-001 monotherapy data remain on track for the first quarter of 2027, and patient dosing began in CR-002’s global APOLLO trial.
